Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GFER | P55789 | 2/20 | 0.44 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.42 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.42 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CASP7 | P55210 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 3/20 | 0.39 |
| ▸ | PPARD | Q03181 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2736868 | 0.89 | GFER (0.50) | GFERMAPTHSD17B10ALDH1A1LMNA | |
| SCHEMBL9131647 | 0.86 | GFER (0.42) | GFERTLR9TLR8TLR7HRH3 | |
| SCHEMBL17785982 | 0.86 | GFER (0.41) | GFERTLR9TLR8TLR7HRH3 | |
| SCHEMBL29402976 | 0.86 | GFER (0.41) | GFERTLR9TLR8TLR7HRH3 | |
| SCHEMBL6421470 | 0.86 | MAPT (0.50) | GFERHRH3KDM4EMAPTHSD17B10 | |
| SCHEMBL18521866 | 0.83 | GFER (0.47) | GFERTLR9TLR8TLR7HRH3 | |
| SCHEMBL20890014 | 0.83 | GFER (0.40) | GFERTLR9TLR8TLR7HRH3 | |
| SCHEMBL21466007 | 0.82 | GFER (0.46) | GFERTLR9TLR8TLR7HRH3 | |
| SCHEMBL20889579 | 0.82 | GFER (0.40) | GFERTLR9TLR8TLR7HRH3 | |
| SCHEMBL30857346 | 0.81 | KDM4E (0.47) | GFERKDM4EMAPTPPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203087-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-06-29 | — | — | US | disclosed |
| US-20230150993-A1 | ANTIPROLIFERATION COMPOUNDS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2023-05-18 | — | — | US | disclosed |
| US-20230118115-A1 | SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINES AS WEE1 INHIBITORS | INTEGRAL BIOSCIENCES PVT. LTD. (IN) | 2023-04-20 | — | — | US | disclosed |
| US-20230062712-A1 | ANTI-ASGR1 ANTIBODY CONJUGATES AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-11541126-B1 | Anti-ASGR1 antibody TLR8 agonist comprising conjugates and uses thereof | SILVERBACK THERAPEUTICS, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-11345694-B2 | Antibacterial compounds | DISCUVA LTD. (GB) | 2022-05-31 | — | — | US | disclosed |
| US-11332473-B2 | Substituted pyrazolo[3,4-d]pyrimidines as Wee1 inhibitors | NUVATION BIO INC. (US) | 2022-05-17 | — | — | US | disclosed |
| EP-3949969-A2 | BENZAZEPINE COMPOUNDS, CONJUGATES, AND USES THEREOF | Silverback Therapeutics, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| US-20220024939-A1 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES | RECURIUM IP HOLDINGS, LLC | 2022-01-27 | — | — | US | disclosed |
| WO-2022000443-A1 | METHODS AND COMPOSITIONS FOR TARGETING TREGS USING CCR8 INHIBITORS | Nanjing Immunophage Biotech Co., Ltd. (CN) | 2022-01-06 | — | — | WO | disclosed |
| US-20110171159-A1 | Glycoside Derivatives and Uses Thereof | NOVARTIS AG (CH) | 2011-07-14 | — | — | US | disclosed |
| US-20110171159-A1 | Glycoside Derivatives and Uses Thereof | NOVARTIS AG (CH) | 2011-07-14 | — | — | US | disclosed |
| US-20110118285-A1 | HETEROCYCLES AS PROTEIN KINASE INHIBITORS | AMGEN INC. | 2011-05-19 | — | — | US | disclosed |
| US-20100311735-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BOEHRINGER INGLEHEIM INTERNATIONAL GMBH (DE) | 2010-12-09 | — | — | US | disclosed |
| US-20090318436-A1 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2009-12-24 | — | — | US | disclosed |
| US-20090124612-A1 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-20090124612-A1 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-20090124609-A1 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-20070105865-A1 | Substituted bicyclic quinazolin-4-ylamine derivatives | NEUROGEN CORPORATION (US) | 2007-05-10 | — | — | US | disclosed |
| US-20070105865-A1 | Substituted bicyclic quinazolin-4-ylamine derivatives | NEUROGEN CORPORATION (US) | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318436-A1 | Fused heterocyclic derivatives and methods of use | HGF, HGFAC, MET | GFER 1976/4885TLR9 719/4885TLR8 1329/4885 |
| US-20070105865-A1 | Substituted bicyclic quinazolin-4-ylamine derivatives | PIGS, HRH4, GPR35 | GFER 4233/4885TLR9 652/4885TLR8 138/4885 |
| US-20230118115-A1 | SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINES AS WEE1 INHIBITORS | WEE1, WEE2, DPYD | GFER 3197/4885TLR9 4234/4885TLR8 4049/4885 |
| US-20090124612-A1 | Fused heterocyclic derivatives and methods of use | HGF, HGFAC, MET | GFER 1976/4885TLR9 719/4885TLR8 1329/4885 |
| US-11345694-B2 | Antibacterial compounds | CFTR, MRPL21, NQO1 | GFER 1118/4885TLR9 139/4885TLR8 133/4885 |
| US-20230062712-A1 | ANTI-ASGR1 ANTIBODY CONJUGATES AND USES THEREOF | ASGR1, HAVCR2, FCGR2A | GFER 2377/4885TLR9 213/4885TLR8 484/4885 |
| US-20230203087-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | RNGTT, NSUN2, ALKBH1 | GFER 2710/4885TLR9 233/4885TLR8 719/4885 |
| US-20110118285-A1 | HETEROCYCLES AS PROTEIN KINASE INHIBITORS | HGF, HGFAC, MET | GFER 3313/4885TLR9 2498/4885TLR8 2816/4885 |
| US-20230150993-A1 | ANTIPROLIFERATION COMPOUNDS AND USES THEREOF | MKI67, MCL1, CCNI | GFER 4268/4885TLR9 4622/4885TLR8 4719/4885 |
| US-20220024939-A1 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES | MKI67, BRCA1, CCNI | GFER 4800/4885TLR9 4086/4885TLR8 3886/4885 |
| US-20110171159-A1 | Glycoside Derivatives and Uses Thereof | SLC5A1, SLC5A2, SLC2A1 | GFER 1470/4885TLR9 1889/4885TLR8 1510/4885 |
| US-11332473-B2 | Substituted pyrazolo[3,4-d]pyrimidines as Wee1 inhibitors | WEE1, WEE2, DPYD | GFER 3197/4885TLR9 4234/4885TLR8 4049/4885 |
| US-20090124609-A1 | Fused heterocyclic derivatives and methods of use | HGF, HGFAC, MET | GFER 1976/4885TLR9 719/4885TLR8 1329/4885 |
| US-11541126-B1 | Anti-ASGR1 antibody TLR8 agonist comprising conjugates and uses thereof | ASGR1, TLR8, HAVCR2 | GFER 2302/4885TLR9 6/4885TLR8 2/4885 |
| US-20100311735-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | RTF2, REV1, POLR1E | GFER 2945/4885TLR9 3785/4885TLR8 4430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.